21 results
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
12 Jan 24
Current report (foreign)
7:43am
. See Note 18.
Until such time that the Company implements its growth strategy, it expects to continue to generate operating losses … that the Company implements its growth strategy, it expects to continue to generate operating losses in the foreseeable future, mostly due
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
8 Nov 23
Current report (foreign)
4:11pm
of McKinsey & Co., a consulting firm, focusing on private equity, healthcare and life sciences transactions, and growth strategy work for specialty pharma
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
1 Sep 23
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum
7:37am
as the execution of the Company's go-to-market strategy for ViraxImmune™. Prior to joining Virax, Dr. McCracken was the Chief Scientific Officer at BerGenBio AsA … of corporate strategy. Dr. McCracken obtained a Master’s degree in Clinical Pharmacology from Kings College London, a Doctor of Philosophy degree
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
15 Nov 22
Virax Biolabs Appoints Richard Pallin as the Vice President of In Vitro Diagnostic Sales
7:36am
Virax’s commercial team and lead the execution of the Company’s go-to-market strategy. Prior to joining Virax, Mr. Pallin was the Vice President of Global
20-F
s39g3 iup4ful
12 Aug 22
Annual report (foreign)
4:20pm
424B4
pjzpt1otqsty ahc6
21 Jul 22
Prospectus supplement with pricing info
10:01am
FWP
q1346d3y0bl7q 5c7w7
30 Jun 22
Free writing prospectus
9:04pm
FWP
gmr c1fforlxnvqf
30 Jun 22
Free writing prospectus
1:29pm
F-1/A
9jm6nt j5h592fg4
24 Jun 22
Registration statement (foreign) (amended)
9:47pm
F-1/A
goe41m
24 Jun 22
Registration statement (foreign) (amended)
8:21am
F-1/A
92f7262dbpduo6ogo
21 Jun 22
Registration statement (foreign) (amended)
6:26am
F-1/A
2cxj9df4d4rano0
6 Jun 22
Registration statement (foreign) (amended)
6:13pm
F-1/A
me61lcm7s69
11 May 22
Registration statement (foreign) (amended)
3:11pm
F-1/A
tm258f
22 Apr 22
Registration statement (foreign) (amended)
6:09pm
F-1
5ou6skdlbhnny1hng
18 Mar 22
Registration statement (foreign)
3:50pm
CORRESP
iuuj11
18 Mar 22
Correspondence with SEC
12:00am
DRSLTR
z2og2mit088 aom
17 Feb 22
Correspondence regarding draft registration statement
12:00am
DRS/A
n2uhf1dmg6nvbmq3w
17 Feb 22
Draft registration statement (amended)
12:00am
UPLOAD
gfsj6
28 Jan 22
Letter from SEC
12:00am